IceCure Medical Highlights ProSense® Advances at EUSOBI Conference
IceCure Medical Ltd. (NASDAQ: ICCM) has garnered significant attention at the recent European Society of Breast Imaging (EUSOBI) annual conference with its innovative ProSense® cryoablation technology. This minimally invasive method, which targets tumor destruction via freezing, was central to six groundbreaking studies presented at the event.
Recognition for Innovative Research
One of the standout features of the conference was the award-winning ICE3 trial, led by Co-Principal Investigator Dr. Kenneth Tomkovich. His presentation earned the prestigious EUSOBI 2024 Abstract Award, reflecting the high regard for research that emphasizes the safety and efficacy of cryoablation as a primary treatment option for low-risk breast cancers. Dr. Tomkovich highlighted the trial's impressive findings, including a remarkable 96.3% recurrence-free rate among patients treated with ProSense® and complementary endocrine therapy.
Significance of EUSOBI Recognition
Dr. Tomkovich expressed his pride in having a U.S.-based study recognized by a leading European medical society, underscoring the potential of cryoablation for advancing treatment options worldwide. This acknowledgment positions IceCure Medical at the forefront of innovation in breast cancer treatment.
THERMAC Trial Showcases Efficacy
The conference also featured the THERMAC trial from the Netherlands, which was honored with the EUSOBI Young Physician Scientist Prize. This trial compared several percutaneous thermal ablation techniques, revealing that cryoablation achieved a 94% complete ablation rate without any recorded adverse events. These results reinforce cryoablation's status as the safest and most effective treatment option compared to radiofrequency and microwave methods.
Growing Demonstration of Evidence
In addition to the award-winning studies, IceCure Medical's presence at the EUSOBI conference allowed professionals to engage with live demonstrations of the ProSense® system. Breast cryoablation experts such as Dr. Lucía Graña-López and Dr. Federica Di Naro participated in Q&A sessions, sharing their insights and experiences with the technology. Both experts have contributed to prior studies affirming ProSense®'s effectiveness in treating breast tumors.
Impact of ProSense® in Europe
The substantial attendance at the conference, exceeding 1700 professionals, provided a unique opportunity for IceCure Medical to showcase the ProSense® Cryoablation System's approved indications for treating both breast cancer and fibroadenoma in Europe. This exposure not only highlights the system's capabilities but also reflects IceCure’s strategic focus on expanding its market presence.
Inspiring Future Collaborations
According to IceCure's CEO Eyal Shamir, the positive reception at EUSOBI opens doors for future collaborations with medical facilities aiming to offer safer, minimally invasive treatment options to their patients. Shamir's vision for ProSense® indicates a commitment to enhancing patient outcomes globally through widespread adoption.
Study Summaries from EUSOBI Presentations
A comprehensive overview of the six presented abstracts underscores the progressive nature of cryoablation research. Highlights include:
- ICE3 Trial: Commended for its 5-year recurrence rate of 4.3%, comparable to traditional surgical methods.
- THERMAC Trial: Cryoablation's efficacy was affirmed as the safest method, achieving a 94% ablation rate without adverse effects.
- Patient Satisfaction Study: Indicated greater aesthetic satisfaction following cryoablation than surgical approaches.
- Ultrasound-guided Cryoablation Study: Showed improvement in pain management and quality of life in patients.
- Single-center Cryoablation Study in Romania: Demonstrated safety and effectiveness for benign and malignant tumor treatments.
- Fibroadenoma Cryoablation Study in Hungary: Reported a 92.9% reduction in tumor volume within a year post-procedure.
About IceCure Medical
IceCure Medical is committed to developing and marketing advanced cryoablation therapy systems, primarily targeting treatments for tumors across various types including breast, kidney, and lung cancers. The ProSense® system represents a significant leap forward in minimally invasive cancer care, making procedures safer and less invasive for patients.
Frequently Asked Questions
What is ProSense® and how does it work?
ProSense® is a cryoablation system developed by IceCure Medical that uses freezing techniques to destroy abnormal breast tissues, offering a less invasive alternative to surgery.
What were the key highlights from the EUSOBI conference?
The EUSOBI conference showcased six studies on ProSense®, highlighted Dr. Tomkovich's award-winning research, and demonstrated the technology through live sessions.
What are the implications of the ICE3 trial results?
The ICE3 trial results, showing a 96.3% recurrence-free rate, demonstrate that cryoablation can be a safe alternative to surgical options for low-risk breast cancer patients.
How does cryoablation compare to other treatments?
Cryoablation has shown superior efficacy and safety compared to methods like radiofrequency and microwave in several studies presented at the conference.
Where is ProSense® available for treatment?
ProSense® has received regulatory approval for use in various locations, including the U.S., Europe, and China, broadening its accessibility for patients.
